- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy | 5 | Investing.com | ||
| 14.11. | Eterna Therapeutics erfüllt wieder Nasdaq-Anforderungen und konzentriert sich auf Krebstherapie | - | Investing.com Deutsch | ||
| 14.11. | Eterna Therapeutics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 14.11. | Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing | 43 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") announced today that it has regained compliance with Nasdaq for continued listing... ► Artikel lesen | |
| 12.11. | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Eterna Therapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| ETERNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.11. | Eterna Therapeutics-Aktionär Charles Cherington verkauft Aktien im Wert von 6,54 Millionen US-Dollar | - | Investing.com Deutsch | ||
| 30.10. | Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success | 56 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring... ► Artikel lesen | |
| 29.10. | Eterna Therapeutics announces share issuance and executive agreements | 1 | Investing.com | ||
| 29.10. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases | 118 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license... ► Artikel lesen | |
| 27.09. | Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics droht Delisting von der Nasdaq aufgrund von Eigenkapitalmangel | 1 | Investing.com Deutsch | ||
| 23.09. | Eterna Therapeutics faces Nasdaq delisting over equity shortfall | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.12.23 | Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer | 242 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,900 | +1,70 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,850 | +2,95 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,810 | +1,38 % | Bio-Path-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,79 US-Dollar |
Das Unternehmen ETERNA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,29 % bei einem Aktienkurs von 0,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ETERNA THERAPEUTICS INC finden Sie auf Wallstreet Online.
